BioCentury | Oct 31, 2019
Company News
Backed by Morningside, Pinteon’s first clinical program targets toxic tau isoform
...protein tau
Paul Bonanos, Associate Editor
Microtubule-associated protein tau (tau) (MAPT) (FTDP-17)
Protein peptidylprolyl cis/trans isomerase NIMA-interacting 1 (PIN1)
Pinteon Therapeutics...
